BioAge Labs, Inc (BIOA) Stock Forecast
BIOA analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.20 / 5 from 10 analysts
- Price target
- $32.56 average of analyst targets
- Upside to target
- +572.6% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.68
- 52-week range
- $4.84 – $25.10
BIOA analyst ratings
10 analystsNumber of analysts at each rating.
BIOA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BIOA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.63 | −$0.69 | −$0.52 | −$0.56 | −11.8% | 8 |
| Current fiscal year (2026) | −$2.43 | −$2.77 | −$2.14 | −$2.24 | −8.3% | 8 |
| Next fiscal year (2027) | −$2.50 | −$3.12 | −$1.89 | −$2.43 | −3.2% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BIOA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.5M | $0 | $3.0M | −28.1% | 10 |
| Current fiscal year (2026) | $7.5M | $5.0M | $10.4M | −16.3% | 11 |
| Next fiscal year (2027) | $14.9M | $0 | $83.3M | +97.7% | 11 |
BIOA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BIOA revenue: reported and forecast
BIOA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.66 | −$0.61 | −$0.61 | −$0.61 | −$0.63 | −4.6% | 2 up · 1 down |
| Current fiscal year (2026) | −$2.49 | −$2.37 | −$2.37 | −$2.37 | −$2.43 | −2.6% | 2 up · 2 down |
| Next fiscal year (2027) | −$2.06 | −$2.36 | −$2.41 | −$2.41 | −$2.50 | +21.5% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BIOA earnings surprises
Reported EPS vs the consensus estimate for the last 9 quarters; BIOA beat in 3 of 9.
What analysts expect from BIOA
10 analysts cover BioAge Labs; their consensus rating is buy (4.20 on a 1–5 scale, where 5 is a strong buy). The average price target is $32.56, 572.6% above the latest close of $4.84. Analysts expect earnings of −$2.43 per share for 2026, −8.3% from a year earlier. For 2027 the average estimate is −$2.50 per share on revenue of $14.9 million. BioAge Labs beat the EPS estimate in 3 of the last 9 quarters.
Related: BIOA income statement, BIOA key metrics, BIOA chart. See the BIOA stock overview for the latest quote and news.
BIOA forecast FAQ
What is BioAge Labs's price target?
The average analyst price target for BioAge Labs is $32.56, 572.6% above the latest close of $4.84.
Is BioAge Labs a buy, hold or sell?
Of 10 analysts covering BioAge Labs, 5 rate it a strong buy, 2 a buy, 3 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is BioAge Labs's EPS forecast?
Analysts forecast −$2.43 per share for 2026 (range −$2.77 to −$2.14); for 2027 the estimate is −$2.50.
What is BioAge Labs's revenue forecast?
The average revenue estimate for 2026 is $7.5 million, growth of −16.3%; for 2027 it is $14.9 million.
When does BioAge Labs report earnings?
BioAge Labs is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.68.
Does BioAge Labs usually beat earnings estimates?
BioAge Labs reported EPS at or above the analyst estimate in 3 of the last 9 quarters.